Please Wait
Applying Filters...
menu
    • menu
    munit-sa-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Tildrakizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    $ API Ref.Price (USD/KG) : 303Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ilumya Effective In Moderate-To-Severe Nail Psoriasis At AAD 2025
    Ilumya Effective In Moderate-To-Severe Nail Psoriasis At AAD 2025

    07 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ilumya-tildrakizumab-asmn-found-effective-for-treatment-of-moderate-to-severe-plaque-psoriasis-affecting-nails-in-study-presented-at-2025-aad-conference-302395300.html

    PR NEWSWIRE
    07 Mar 2025
    Share Share
    Almirall To Present New Psoriasis Atopic Dermatitis Data
    Almirall To Present New Psoriasis Atopic Dermatitis Data

    23 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240923201861/en

    BUSINESSWIRE
    23 Sep 2024
    Share Share
    Sun Pharma's Ilumya (Tildrakizumab asmn) Receives Suppl Approval in the U.S.
    Sun Pharma's Ilumya (Tildrakizumab asmn) Receives Suppl Approval in the U.S.

    04 Apr 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761067

    FDA
    04 Apr 2024
    Share Share
    Sun Pharma specialty drug Tildrakizumab makes it to China's reimbursement list
    Sun Pharma specialty drug Tildrakizumab makes it to China's reimbursement list

    13 Dec 2023

    // ECONOMIC TIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-specialty-drug-tildrakizumab-makes-it-to-chinas-reimbursement-list/articleshow/105967100.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

    ECONOMIC TIMES
    13 Dec 2023
    Share Share
    Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing
    Almirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing

    11 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231011690776/en

    BUSINESSWIRE
    11 Oct 2023
    Share Share
    Almirall: Ilumetri improved the wellbeing of patients with plaque psoriasis
    Almirall: Ilumetri improved the wellbeing of patients with plaque psoriasis

    07 Jul 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230707896992/en

    BUSINESSWIRE
    07 Jul 2023
    Share Share